We proactively attract R&D personnel with innovative abilities and providing basic technical support for the expansion of R&D innovative pipeline based on master and doctoral talents experienced in biomedicine. The R&D personnel of the Group accounted for nearly 28.71% of total employees, and approximately 47.09% of R&D personnel had master’s degrees or above.

The company continues to invest in research and development, with R&D investment accounting for a higher proportion of operating revenue than the industry level, in order to inject innovative vitality.

Our R&D center has a floor space of more than 17,000 square meters, with various advanced labs. •Over 20,000 square meters •Advanced laboratory facilities •World-class R&D equipment

We have been granted 65 patents, of which 48 are invention patents.

We have published 8 research papers in the world's top medical journals, including The Lancet and Nature.

While doing R&D on our own, we have also entered into multiple partnerships with research organizations worldwide, including National Research Council Canada, BIRD-C, Vaccitech and so on. In addition, we have established joint training programs with multiple esteemed universities, such as Peking University and Nankai University, to cultivate talented young people.